Pfizer Covid-19 vaccine
German company BioNTech and US pharmaceutical company Pfizer say data on their coronavirus vaccine were unlawfully accessed during a cyberattack on the servers of the European Medicines Agency.
The Amsterdam-based agency, which is considering requests for conditional marketing authorisation for several coronavirus vaccines to be used in the 27-nation European Union, said earlier on Wednesday that it had been the target of a cyberattack.
The EMA declined to provide more details of the attack while the investigation was continuing, but the two companies later released a statement saying that some documents relating to the regulatory submission for Pfizer and BioNTech's COVID-19 vaccine candidate, BNT162b2, which has been stored on an EMA server, had been unlawfully accessed.
They added that no BioNTech or Pfizer systems had been breached in connection with the incident and that they weren't aware that any study participants had been identified as a result of the data being accessed.
"At this time, we await further information about EMA's investigation and will respond appropriately and in accordance with EU law, the companies said. EMA has assured us that the cyber attack will have no impact on the timeline for its review.
The vaccine made by BioNTech and Pfizer became the first to be granted emergency authorization in Britain last week, and in Canada on Wednesday. The US FDA is expected to consider a submission for approval on Thursday.
It would not be the first time an entity linked with coronavirus vaccines has been targeted by cybercriminals.
Last month, Microsoft said it had detected attempts by state-backed Russian and North Korean hackers to steal valuable data from leading pharmaceutical companies and vaccine researchers.
Microsoft said most of the targets located in Canada, France, India, South Korea and the United States were directly involved in researching vaccines and treatments for COVID-19". It did not name the targets but said most had vaccine candidates in various stages of clinical trials.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.